Histone Deacetylase 2 - Pipeline Review, H2 2019
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 18.104.22.168) - Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity.
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 22.214.171.124) pipeline Target constitutes close to 29 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 1, 12 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Melanoma, Mycosis Fungoides, Alzheimer's Disease, B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Burkitt Lymphoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Parkinson's Disease, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Bone Disorders, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Depression, Duchenne Muscular Dystrophy, Epithelial Ovarian Cancer, Gallbladder Cancer, Gliosarcoma, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Lewy Body Dementia, Liver Fibrosis, Lung Cancer, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Sclerosis, Myelofibrosis, Natural Killer Cell Lymphomas, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Pick Disease, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sezary Syndrome, Sickle Cell Disease, Solid Tumor, Systemic Lupus Erythematosus and Thalassemia.
The latest report Histone Deacetylase 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 126.96.36.199) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 188.8.131.52) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook